Paeds Cases · haematology-oncology-and-transfusion
Neutropenia and neutrophil disorders: Case
Clinical long case of an infant presenting with recurrent mouth ulcers and skin infections in whom severe congenital neutropenia is diagnosed, covering the recognition of a congenital production-failure neutropenia, the severity grading, the neutrophil kinetic model, the marrow maturation arrest, the inherited neutropenia gene panel with an ELANE result, the lifelong granulocyte colony-stimulating factor management and the annual marrow surveillance for myelodysplastic syndrome and acute myeloid leukaemia, and the family counselling.
On this page & tools
Target exams
This infant has a severe, isolated, persistent neutropenia presenting with recurrent pyogenic infections of the mucosa and skin, in a child with otherwise normal growth and cell lines. The pattern points away from a benign post-viral dip or an immune cause and toward a congenital production-failure neutropenia, most likely severe congenital neutropenia. The candidate should synthesise the problem representation aloud: a severe isolated chronic neutropenia with recurrent pyogenic infections in an infant is a congenital neutropenia syndrome, most often ELANE-related severe congenital neutropenia, until proven otherwise. [2][1]
Clinical findings and the differential
The key findings are the profound absolute neutrophil count of 0.1 times ten to the ninth per litre, confirmed on a repeat sample, with a normal haemoglobin and platelet count, and recurrent pyogenic infections of the surfaces the neutrophil defends: the mouth, the skin, and the ears. The severity grading places this firmly in the severe band, with infection risk at its highest and counts under 0.1 considered profound. The film excludes the acute alternative diagnoses: there are no blasts to suggest leukaemia, no dysplasia to suggest myelodysplasia, and no giant intracytoplasmic granules to suggest Chediak-Higashi. [1]
The differential of a severe isolated chronic neutropenia in an infant is led by the congenital disorders. Severe congenital neutropenia, most often ELANE-related and autosomal dominant, fits the severe persistent neutropenia, the early onset, and the recurrent pyogenic infections. The autosomal recessive HAX1 form (Kostmann disease) is possible but classically described in northern Scandinavian families. Cyclic neutropenia is excluded by the absence of a regular twenty-one day cycle. Autoimmune neutropenia of infancy usually gives a milder count and is confirmed by anti-neutrophil antibodies. The candidate should name the kinetic mechanism: this is a production failure, a maturation arrest in the marrow. [2][6]
Investigations and the gene panel
The candidate should order the targeted workup. Anti-neutrophil antibodies exclude autoimmune neutropenia. A bone marrow aspirate and trephine with cytogenetics is essential in a severe persistent neutropenia: the expected finding in severe congenital neutropenia is a maturation arrest at the promyelocyte stage, and the cytogenetics set a baseline for the annual surveillance. An inherited neutropenia gene panel covering ELANE, HAX1, SBDS, CXCR4, GATA2, LYST and TAZ is sent, and an ELANE mutation is the expected result here. The candidate should explain to the family in plain language that the gene result will confirm the diagnosis and inform the counselling of the family, including the autosomal dominant inheritance and the small chance that a parent carries the mutation. [6][1]
The candidate should hold the kinetic model while interpreting these tests. The marrow maturation arrest, the severe persistent count, and the recurrent pyogenic infections together localise the mechanism to production failure at the promyelocyte stage, and the ELANE result confirms the misfolded neutrophil elastase that drives the unfolded-protein-response apoptosis. The film's exclusion of blasts and the normal other cell lines keep the focus on a congenital neutropenia rather than a marrow infiltrate or aplasia. [6]
Management
The management has three pillars: lifelong granulocyte colony-stimulating factor, antimicrobial prophylaxis and oral hygiene, and annual marrow surveillance. The cornerstone is granulocyte colony-stimulating factor (filgrastim or lenograstim) given subcutaneously, started at a low dose and titrated to an absolute neutrophil count that prevents infection, most often a target in the 1.5 to 2.0 band. The Severe Chronic Neutropenia International Registry documented a sustained response and improved survival on long-term filgrastim, and the family is taught home injection. [3]
Antimicrobial prophylaxis with co-trimoxazole for Pneumocystis and an antifungal agent is added for chronic severe neutropenia, and fastidious oral hygiene protects the periodontium that the absent neutrophils cannot defend. The annual marrow with cytogenetics is non-negotiable, because the cumulative risk of myelodysplastic syndrome and acute myeloid leukaemia is roughly twenty per cent over ten years on granulocyte colony-stimulating factor, and the acquisition of clonal cytogenetic abnormalities such as CSF3R mutations, monosomy 7 or trisomy 21 is the harbinger that changes management. Haematopoietic stem cell transplant is reserved for transformation to myelodysplastic syndrome or acute myeloid leukaemia. The candidate should name the first-hour febrile-neutropenia rule for the family: any fever of 38.5 degrees Celsius or higher must be assessed urgently, with blood cultures and empiric intravenous anti-pseudomonal beta-lactam within the first hour. [4][1]
Discharge counselling and follow-up
The discharge plan is the heart of the long case, because severe congenital neutropenia is a lifelong, technology-dependent condition. The family is taught home granulocyte colony-stimulating factor injection, given a written fever action plan and a medical alert, and enrolled in annual marrow surveillance. The candidate should explain the autosomal dominant inheritance, the small chance that a parent carries the ELANE mutation, and the option of testing the parents and any siblings. The paternal uncle with recurrent skin infections is a clue that the family should be offered testing. [2][5]
The candidate should address the long-term outlook honestly. The prognosis on long-term granulocyte colony-stimulating factor is markedly improved, but it carries the cumulative leukaemia and sepsis risk that drives the surveillance. The child is enrolled in a coordinated multidisciplinary service across haematology, infectious diseases, dentistry, genetics and psychology, with a planned transition to adult care. The candidate should close by affirming the single non-negotiable safety-net that applies to every child with neutropenia, regardless of cause: fever in a severely neutropenic child is a same-hour emergency. [3][1]
References
- [1]Newburger PE, Dale DC Evaluation and management of patients with isolated neutropenia. Semin Hematol, 2013.PMID 23953336
- [2]Welte K, Zeidler C, Dale DC Severe congenital neutropenia. Semin Hematol, 2006.PMID 16822461
- [3]Dale DC, Cottle TE, Fier CJ, et al Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol, 2003.PMID 12555210
- [4]Rosenberg PS, Alter BP, Bolyard AA, et al The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood, 2006.PMID 16497969
- [5]Makaryan V, Zeidler C, Bolyard AA, et al The diversity of mutations and clinical outcomes for ELANE-associated neutropenia. Curr Opin Hematol, 2015.PMID 25427142
- [6]Horwitz MS, Corey SJ, Grimes HL, et al ELANE mutations in cyclic and severe congenital neutropenia: genetics and pathophysiology. Hematol Oncol Clin North Am, 2013.PMID 23351986